Bio-Rad Laboratories (BIO) Given Daily News Sentiment Score of 0.15
News headlines about Bio-Rad Laboratories (NYSE:BIO) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bio-Rad Laboratories earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 47.1326579103274 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern’s analysis:
- Middle East and Africa Proteins Assays Market is Growing Y-O-Y From Forecast period 2016-2021 (reports.pr-inside.com)
- Genomics Market Will Grow Rapidly Based On Increasing Prevalence Of Fetal Disorder Such As Cancer And Diabetes Till 2020: Grand View Research, Inc. (medgadget.com)
- Multiplex Assay Market 2017: Global Industry Survey Report with Growth Analysis (sbwire.com)
- Report explores the Middle East and Africa immunohistochemistry market (whatech.com)
- In Vitro Diagnostics (IVD) and Laboratory Developed Tests for Autoimmune Diseases Market : Estimated to Flourish by 2025 (sbwire.com)
Several equities research analysts have issued reports on BIO shares. Deutsche Bank AG raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating and cut their price target for the company from $220.00 to $195.00 in a report on Wednesday, June 28th. BidaskClub raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $275.00 price target on shares of Bio-Rad Laboratories in a report on Friday, July 14th. TheStreet downgraded Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday, August 3rd. Finally, Zacks Investment Research raised Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $260.00.
Shares of Bio-Rad Laboratories (BIO) opened at 223.89 on Friday. Bio-Rad Laboratories has a 12-month low of $154.89 and a 12-month high of $242.79. The stock’s 50 day moving average price is $222.39 and its 200-day moving average price is $220.85. The firm has a market cap of $6.64 billion, a P/E ratio of 442.47 and a beta of 0.91.
In other news, EVP Michael Crowley sold 700 shares of the company’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the transaction, the executive vice president now owns 2,060 shares of the company’s stock, valued at approximately $444,774.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 28.29% of the stock is owned by corporate insiders.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.